US 11793796
Inhibition of crystal growth of roflumilast
granted A61KA61K31/44A61K45/06
Quick answer
US patent 11793796 (Inhibition of crystal growth of roflumilast) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ARCUTIS BIOTHERAPEUTICS, INC.
- Grant date
- Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K31/44, A61K45/06, A61K47/10, A61K9/0014